Similarly, CKS1B expression has been reported to be high in CML patients at blast crisis and, further to this, significantly reduced after imatinib (STI-571) treatment [47]. The gene discussed is CKS1B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.